DexCom (NASDAQ:DXCM) Posts Quarterly Earnings Results, Beats Expectations By $0.09 EPS

DexCom (NASDAQ:DXCM) announced its quarterly earnings results on Thursday. The medical device company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.09, Zacks reports. The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The firm’s quarterly revenue was up 15.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.32 earnings per share.

Here are the key takeaways from DexCom’s conference call:

• Company reported Q1 revenue of $1.19 billion (up 15% YoY, organic +12%), with gross margin improving to 63.5%, operating income and adjusted EBITDA up materially, and management reaffirmed FY revenue guidance while raising operating profit and EBITDA margin guidance.
• Product momentum from the G7 15‑Day rollout was strong — customers praised the longer wear and improved algorithm (company estimates ~50% of base will convert by year‑end) — and Dexcom is deploying adhesive and software (Stelo redesign, Smart Basal pilot) updates to further drive adoption and retention.
• Payer access is expanding — Prime Therapeutics will cover Dexcom CGM for commercial type‑2 non‑insulin patients this summer, putting coverage at >7 million non‑insulin lives by year‑end, and a randomized control trial readout at ADA 2026 is expected to support broader reimbursement efforts.
• Management reiterated gross margin guidance but flagged a 50–100 bps potential headwind from geopolitical/fuel and resin price uncertainty, leaving timing for broader CMS coverage for type‑2 non‑insulin patients still uncertain.
• Cash generation was strong — ending the quarter with ~$2.4 billion in cash and significant free cash flow — giving flexibility for capital allocation (buybacks, tuck‑ins, manufacturing investments) that management plans to discuss at Investor Day.

DexCom Stock Performance

Shares of DXCM stock traded up $1.80 during mid-day trading on Friday, reaching $61.35. 10,561,308 shares of the company’s stock traded hands, compared to its average volume of 4,931,596. DexCom has a 12 month low of $54.11 and a 12 month high of $89.98. The firm has a 50 day moving average price of $65.87 and a two-hundred day moving average price of $66.40. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.59 and a current ratio of 1.88. The firm has a market capitalization of $23.67 billion, a PE ratio of 29.21, a price-to-earnings-growth ratio of 1.12 and a beta of 1.55.

Insider Activity

In other news, EVP Michael Jon Brown sold 1,700 shares of the business’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total transaction of $107,168.00. Following the completion of the sale, the executive vice president owned 111,204 shares of the company’s stock, valued at $7,010,300.16. The trade was a 1.51% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.32% of the stock is currently owned by insiders.

Institutional Investors Weigh In On DexCom

Hedge funds have recently modified their holdings of the business. DV Equities LLC bought a new stake in shares of DexCom during the 4th quarter valued at $36,000. Aster Capital Management DIFC Ltd bought a new stake in shares of DexCom during the 4th quarter valued at $63,000. Quarry LP bought a new stake in shares of DexCom during the 3rd quarter valued at $72,000. MUFG Securities EMEA plc bought a new stake in shares of DexCom during the 2nd quarter valued at $100,000. Finally, Summit Securities Group LLC grew its position in shares of DexCom by 817.2% during the 4th quarter. Summit Securities Group LLC now owns 1,174 shares of the medical device company’s stock valued at $78,000 after acquiring an additional 1,046 shares during the period. Institutional investors own 97.75% of the company’s stock.

Analysts Set New Price Targets

DXCM has been the subject of a number of research analyst reports. Weiss Ratings raised shares of DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, March 4th. Morgan Stanley reaffirmed an “overweight” rating on shares of DexCom in a research report on Monday, January 12th. Raymond James Financial set a $81.00 target price on shares of DexCom in a research report on Friday. Evercore raised shares of DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 target price for the company in a research report on Tuesday, March 24th. Finally, Wells Fargo & Company cut their target price on shares of DexCom from $93.00 to $85.00 and set an “overweight” rating for the company in a research report on Friday, February 13th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and a consensus price target of $83.73.

Key DexCom News

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Q1 beat on both EPS and revenue; non‑GAAP EPS of $0.56 topped estimates and revenue rose 15% to $1.19B with margins improving — a clear near‑term earnings beat that supports upside. DexCom Stock Up on Q1 Earnings & Revenues Beat, Margins Rise
• Positive Sentiment: Company reported record new patient starts globally and cites product momentum plus coverage expansion as drivers — supports sustained top‑line growth and market penetration for its CGM franchise. DXCM Q1 deep dive: US growth moderates as product momentum and coverage expansion drive strategy
• Positive Sentiment: Medicare National Coverage Determination (NCD) remains the biggest catalyst for 2026 per RBC — a favorable NCD could materially expand U.S. addressable market and is being watched by investors. DexCom Medicare Coverage NCD Remains Biggest 2026 Catalyst, RBC Says
• Neutral Sentiment: Management reaffirmed FY26 revenue guidance (~$5.2–$5.3B) rather than raising it; that keeps the outlook intact but removes an upside surprise for the full year amid geopolitical caution. Dexcom reaffirms full-year forecast after topping quarterly estimates
• Negative Sentiment: Some brokerages trimmed price targets (TD Cowen cut to $75; BTIG lowered its PT to $80) even as they keep Buy ratings — reduces near‑term analyst upside and may cap gains. Benzinga
• Negative Sentiment: Shares saw an after‑hours pullback in some sessions despite the beat as investors parsed the lack of an upgraded FY revenue outlook and geopolitical risk; watch volume and guidance commentary in the call transcript/slides. Dexcom falls over 5% despite better-than-expected Q1 print, as revenue guidance disappoints

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.